High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: A case series [1]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 513-514

  Deutschman, Daniel A ^a   Deutschman, Douglas H ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE;

AGITATION; AKATHISIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONCENTRATION TROUBLE; COORDINATION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEADACHE; HUMAN; HYPOMANIA; INSOMNIA; LETTER; MENTAL CONCENTRATION; MENTAL DEFICIENCY; PRIORITY JOURNAL; QT INTERVAL; RESTLESS LEGS SYNDROME; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYNCOPE; TREATMENT DURATION; VISUAL DISORDER; VISUAL TRAIL;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; MOOD DISORDERS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548680075     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814cface     Document Type: Letter

References (5)

1. Warrington L, Loebel A, Yang R. Ziprasidone in the treatment of schizophrenia: evidence for a linear dose-response relationship. Poster presented at: the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
2. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005;10:S1-S20.
3. Murray S, Siu CO, Romano SJ. Optimal dosing of oral ziprasidone: analysis of clinical trial data. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
4. Geodon® (ziprasidone) prescribing information. In: Physicians' Desk Reference, 59th ed. Montvale, NJ: Thompson PDR, 2005; 2609-2615.
5. Miceli JJ, Shiovitz T, Swift RH, et al. Higher-dose ziprasidone is associated with marginal additional QTc increase. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.